Lydia Alvarez-Erviti

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/11882074/publications.pdf

Version: 2024-02-01

		687363	839539	
18	7,148	13	18	
papers	citations	h-index	g-index	
18	18	18	10437	
all docs	docs citations	times ranked	citing authors	

#	Article	IF	CITATIONS
1	Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes. Nature Biotechnology, 2011, 29, 341-345.	17.5	3,595
2	Extracellular vesicle in vivo biodistribution is determined by cell source, route of administration and targeting. Journal of Extracellular Vesicles, 2015, 4, 26316.	12.2	1,077
3	Lysosomal dysfunction increases exosome-mediated alpha-synuclein release and transmission. Neurobiology of Disease, 2011, 42, 360-367.	4.4	612
4	Exosome-mediated delivery of siRNA in vitro and in vivo. Nature Protocols, 2012, 7, 2112-2126.	12.0	484
5	Chaperone-Mediated Autophagy Markers in Parkinson Disease Brains. Archives of Neurology, 2010, 67, 1464-72.	4. 5	440
6	Systemic exosomal siRNA delivery reduced alpha-synuclein aggregates in brains of transgenic mice. Movement Disorders, 2014, 29, 1476-1485.	3.9	384
7	Alpha-synuclein release by neurons activates the inflammatory response in a microglial cell line. Neuroscience Research, 2011, 69, 337-342.	1.9	164
8	The acute inflammatory response to intranigral α-synuclein differs significantly from intranigral lipopolysaccharide and is exacerbated by peripheral inflammation. Journal of Neuroinflammation, 2011, 8, 166.	7.2	137
9	Systemic Exosomal Delivery of shRNA Minicircles Prevents Parkinsonian Pathology. Molecular Therapy, 2019, 27, 2111-2122.	8.2	120
10	Mitochondrial impairment increases FL-PINK1 levels by calcium-dependent gene expression. Neurobiology of Disease, 2014, 62, 426-440.	4.4	49
11	Glial activation precedes alpha-synuclein pathology in a mouse model of Parkinson's disease. Neuroscience Research, 2021, 170, 330-340.	1.9	23
12	DJ-1 is a redox sensitive adapter protein for high molecular weight complexes involved in regulation of catecholamine homeostasis. Human Molecular Genetics, 2017, 26, 4028-4041.	2.9	19
13	Oral subchronic exposure to the mycotoxin ochratoxin A induces key pathological features of Parkinson's disease in mice six months after the end of the treatment. Food and Chemical Toxicology, 2021, 152, 112164.	3.6	16
14	The Two Faces of Exosomes in Parkinson's Disease: From Pathology to Therapy. Neuroscientist, 2022, 28, 180-193.	3.5	9
15	Biomonitoring of Mycotoxins in Plasma of Patients with Alzheimer's and Parkinson's Disease. Toxins, 2021, 13, 477.	3.4	8
16	Impact of endolysosomal dysfunction upon exosomes in neurodegenerative diseases. Neurobiology of Disease, 2022, 166, 105651.	4.4	7
17	siRNA Loaded-Exosomes. Methods in Molecular Biology, 2021, 2282, 395-401.	0.9	2
18	Lack of Parkinsonian Pathology and Neurodegeneration in Mice After Long-Term Injections of a Proteasome Inhibitor in Olfactory Bulb and Amygdala. Frontiers in Aging Neuroscience, 2021, 13, 698979.	3.4	2